The news of Jefferies maintaining a Buy rating on Zentalis Pharma is positive for the stock. However, the lowering of the price target from $120 to $70 may create uncertainty among investors, potentially offsetting the positive impact of the Buy rating. Therefore, the short-term impact on the stock price is expected to be neutral.